On 18 May 2026, the European Medicines Agency published the agenda for the Committee for Medicinal Products for Human Use (CHMP) meeting scheduled for 18-21 May 2026. The meeting will review applications for new marketing authorisations, extensions of therapeutic indications, and safety data for several medicines, impacting patients, healthcare providers, and pharmaceutical companies across the EU.
The CHMP, EMA's scientific committee responsible for human medicines, will evaluate applications for new drugs, including those for rare diseases and advanced therapies. The agenda also includes discussions on post-authorisation safety studies and variations to existing marketing authorisations. Decisions made during this meeting will influence which medicines become available in the EU and under what conditions.
Stakeholders affected include patients awaiting new treatments, particularly those with unmet medical needs; pharmaceutical companies seeking EU-wide approval; national competent authorities that will implement CHMP opinions; and healthcare professionals who prescribe these medicines. The meeting outcomes will also impact EU taxpayers funding healthcare systems, as new approvals may affect drug pricing and reimbursement negotiations.
No prior coverage of this specific meeting exists in recent records. The CHMP holds monthly meetings, and its opinions are typically adopted by the European Commission within a few months, leading to EU-wide marketing authorisations.
← Atlas › News › Health & Lifestyle